References
- Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221–1231.
- Dilokthornsakul P, Valuck RJ, Nair KV, et al. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016;86(11):1014–1021.
- Just the Facts: National Multiple Sclerosis Society [Internet]. 2015 [cited 2021 Feb 8]. Available from: https://www.nationalmssociety.org/nationalmssociety/media/msnationalfiles/brochures/brochure-just-the-facts.pdf
- Types of MS National Multiple Sclerosis Society [Internet]. 2018 [cited 2021 Feb 8]. Available from: https://www.nationalmssociety.org/What-is-MS/Types-of-MS
- Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71(2):129–135.
- Bainbridge JR. Multiple sclerosis. In: DiPiro JTTR, Yee G, Matzke G, editors. Pharmacotherapy: a pathophysiologic approach. New York: McGraw-Hill Medical; 2008. p. 913–926.
- Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286.
- Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–788.
- Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175–187.
- Lizak N, Lugaresi A, Alroughani R, et al. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. J Neurol Neurosurg Psychiatry. 2017;88(3):196–203.
- Palace J, Duddy M, Lawton M, et al. Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme. J Neurol Neurosurg Psychiatry. 2019;90(3):251–260.
- Beiki O, Frumento P, Bottai M, et al. Changes in the risk of reaching multiple sclerosis disability milestones in recent decades: a nationwide population-based cohort study in Sweden. JAMA Neurol. 2019;76(6):665–671.
- Salter A, Thomas N, Tyry T, et al. Employment and absenteeism in working-age persons with multiple sclerosis. J Med Econ. 2017;20(5):493–502.
- Raggi A, Covelli V, Schiavolin S, et al. Work-related problems in multiple sclerosis: a literature review on its associates and determinants. Disabil Rehabil. 2016;38(10):936–944.
- Honarmand K, Akbar N, Kou N, et al. Predicting employment status in multiple sclerosis patients: the utility of the MS functional composite. J Neurol. 2011;258(2):244–249. Feb
- Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing–remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349–1357.
- Benefits for People with Disabilities: Social Security Administration [Internet] [cited 2020 Oct 16]. Available from: https://www.ssa.gov/disability/
- Medicare.gov. Getting Medicare If You Have a Disability [Internet] [cited 2020 Oct 16]. Available from: https://www.medicare.gov/getting-medicare-if-you-have-a-disability
- Medicare.gov. Your Medicare Coverage Choices [Internet] [cited 2020 Oct 16]. Available from: https://www.medicare.gov/what-medicare-covers/your-medicare-coverage-choices
- Biogen. Prescribing Information Tysabri [Internet]. 2020 [cited 2021 Feb 8]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/1215104s959lbl.pdf
- Clinical Classifications Software (CCS) for ICD-9-CM [Internet]. US Department of Health and Human Services; 2020 [cited 2020 Oct 1]. Available from: https://hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp
- Clinical Classification Software (CCS) for ICD-10-PCS [Internet]. US Department of Health & Human Services; 2020 [cited 2020 Oct 1]. Available from: https://www.hcup-us.ahrq.gov/toolssoftware/ccs10/ccs10.jsp
- Drug Approval Package Tysabri (Natalizumab) [Internet]. US Food and Drug Administration; 2004 [cited 2020 Oct 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/125104s000_natalizumab.cfm#.:∼:text=Approval%20Date%3A%2011%2F23%2F2004
- Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord. 2015;8(1):31–45. Jan
- FDA Approves New Drug to Treat Multiple Sclerosis [Internet]. US Food and Drug Administration; 2017 [cited 2020 Oct 1]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-multiple-sclerosis#.:∼:text=On%20March%2028%2C%20the%20U.S.,by%20the%20FDA%20for%20PPMS
- Regnier SA. How does drug coverage vary by insurance type? Analysis of argue formularies in the United States. Am J Manag Care. 2014;20(4):322–331.
- About secondary progressive multiple sclerosis (SPMS) and Mayzent (siponimod) [Internet]. 2019 [cited 2020 May 27]. Available from: https://novartis.gcs-web.com/Novartis-receives-FDA-approval-for-Mayzent-siponimod-the-first-oral-drug-to-treat-secondary-progressive-MS-with-active-disease?_ga=2.100123422.1464010027.1590617682-1984911740.1590617682
- FDA. FDA approves new oral treatment for multiple sclerosis [Internet]. US Food and Drug Administration; 2019 [cited 2020 Oct 10]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-oral-treatment-multiple-sclerosis#:∼:text=The%20U.S.%20Food%20and%20Drug,and%20active%20secondary%20progressive%20disease
- Davio KF. Approves Diroximel Fumarate to Treat Relapsing Forms of MS [Internet]. AJMC; 2019 [cited 2020 Oct 10]. Available from: https://www.ajmc.com/view/fda-approves-diroximel-fumarate-to-treat-relapsing-forms-of-ms
- Marriott JJ, Miyasaki JM, Gronseth G, et al. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74(18):1463–1470.
- Melillo G. FDA Approves Ozanimod for Patients with RMS [Internet]. American Journal of Managed Care [cited 2020 Mar 26]. Available from: https://www.ajmc.com/view/fda-approves-zeposia-ozanimod-for-patients-with-rms
- Hollen CW, Paz Soldán MM, Rinker JR 2nd, et al. The future of progressive multiple sclerosis therapies. Federal practitioner: for the health care professionals of the VA, DoD, and PHS. Suppl. 2020;37(1):S43–s49.
- Bowen K, editor. Multiple Sclerosis (MS) Prevalence, Disease-Modifying Drug (DMD) Therapy Use and Adherence, and Total Medical and Pharmacy Claims Expense Associated with MS in a 15 Million Commercially Insured Population. Boston (MA): AMCP; 2018.
- Higuera L, Carlin CS, Anderson S. Adherence to disease-modifying therapies for multiple sclerosis. J Manag Care Spec Pharm. 2016;22(12):1394–1401. Dec